Bristol-Myers Logo
EU Approves Forxiga for Treatment of Type 2 Diabetes Patients
The European Commission has approved Bristol-Myers Squibb and AstraZeneca's new type 2 diabetes therapy, Forxiga (dapagliflozin), for use in the European Union (EU). Forxiga is a selective and reversible inhibitor of sodium-glucose cotransporter 2 (SGLT2) that works independently of insulin to help remove excess glucose from the body
T1D Exchange
T1D Exchange and Sanofi Team Up For Study Of Diabetes Care in Young Patients
T1D Exchange, a non-profit organization focused on type 1 diabetes, and Sanofi have joined forces in the TEENs registry study, a study aimed at providing a better understanding of how children, adolescents and young adults are currently living with type 1 diabetes and to deliver recommendations for better disease management and patients outcomes.
Blue Circle - Diabetes Symbol
Psychological Support: The Missing Piece in Diabetes Care
I am trying to spread the word to health care professionals to try out a new approach with their diabetes patients, one that involves connecting to them as human beings who need support, not just patients who need medication. It’s Diabetes Awareness Month and I can’t think of a better message to send than: No one is better qualified to change the field of diabetes care than those of us living each day with diabetes.
Novo Nordisk Logo
Degludec, Novo Nordisk’s New Insulin, On Its Way To FDA Approval
The Endocrinologic and Metabolic Drugs Advisory Committee of the United States Food and Drug Administration (FDA) completed its meeting regarding the New Drug Applications (NDA) for Novo Nordisk's insulin degludec (to be marketed under the name Tresiba) and insulin degludec/insulin aspart.
Hospital Food
Bisi had to be admitted to Children’s Hospital in Boston to get her blood sugar down—but also so we could learn about type 1 diabetes and the glucose…